New: NCI-funded clinical trial search
Mednet Logo

In VTE patients who require indefinite anticoagulation, what clinical factors or patient characteristics lead you to continue full-dose anticoagulation rather than reducing to low-dose anticoagulation for extended secondary prevention?

Are there particular thrombophilias or types of VTE that you would feel less comfortable de-escalating to prophylactic dose DOAC after 3-6 months?
1 Answer
Mednet MemberInvited Expert
Hematology · Medical University of South Carolina
Answered on · Updated on

In patients who, in my judgment, require long-term anticoagulation, I usually switch from a therapeutic dose to a reduced (prophylactic) dose after at least six months of treatment. I base this practice on randomized trials that included patients with unprovoked VTE, including those with thrombophil...

Join for free or sign in to see the full answer